Back to Market Feed

Product Information

BENICAR HCT 40-25 MG TABLET is a brand product labeled by Cosette Pharmaceuticals, Inc., priced at $15.6513 per EA under NDC 00713086530. Its NADAC has been published 184 times since Jan 18, 2023.

FDA first approved this application on Jun 5, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

BENICAR HCT 40-25 MG TABLET

olmesartan medoxomil-hydrochlorothiazide
$15.6513per EA

Strength

25; 40 mg/1; mg/1

NDC

00713086530

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

7/22/2026

Approval Type

New Drug (NDA)

FDA Application

NDA021532

FDA Approved

6/5/2003

TE Code

AB

On Market Since

9/1/2022

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for BENICAR HCT 40-25 MG TABLET has been published 184 times since Jan 18, 2023, and over the history we have for it it has risen 31.9%. The table below summarizes its recorded NADAC range and movement.

Current price$15.6513 per EA
All-time high$15.7729 (Mar 11, 2026)
All-time low$11.8660 (Jan 18, 2023)
52-week high$15.7729
52-week low$14.2590
Median price$14.1941
Average price$13.7922
Largest weekly change+10.0% (Sep 25, 2024)
Weeks tracked184
Tracking sinceJan 18, 2023

Price History

1W

N/A

1M

N/A

3M

-0.1%

6M

-0.8%

1Y

+9.8%

3Y

+31.9%

5Y

N/A

All

+31.9%

Last surveyed Jul 22, 2026 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olmesartan medoxomil-hydrochlorothiazide market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

DIURIL 250 MG/5 ML ORAL SUSP
Brand
65649031112•Salix Pharmaceuticals Inc.
$0.2787
per ML
HEMICLOR 12.5 MG TABLET
Brand
50742028530•Ingenus Pharmaceuticals LLC
$0.9570
per EA
HEMICLOR 12.5 MG TABLET
Brand
50742028590•Ingenus Pharmaceuticals LLC
$0.9570
per EA
COZAAR 25 MG TABLET
Brand
78206012101•Organon LLC
$3.3500
per EA
THALITONE 15 MG TABLET
Brand
70199001730•Casper Pharma LLC
$3.5373
per EA
INZIRQO 10 MG/ML ORAL SUSP
Brand
70954052210•ANI Pharmaceuticals, Inc.
$4.4572
per ML
MICARDIS HCT 80-25 MG TABLET
Brand
00597004237•Boehringer Ingelheim Pharmaceuticals Inc.
$4.4768
per EA
MICARDIS HCT 80-12.5 MG TABLET
Brand
00597004437•Boehringer Ingelheim Pharmaceuticals Inc.
$4.4802
per EA
MICARDIS 80 MG TABLET
Brand
00597004137•Boehringer Ingelheim Pharmaceuticals Inc.
$4.4823
per EA
MICARDIS HCT 40-12.5 MG TABLET
Brand
00597004337•Boehringer Ingelheim Pharmaceuticals Inc.
$4.4836
per EA

Frequently asked questions

What is the NADAC price of BENICAR HCT 40-25 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for BENICAR HCT 40-25 MG TABLET, manufactured by Cosette Pharmaceuticals, Inc., is $15.6513 per EA (NDC 00713086530), effective Jul 22, 2026.

How has the price of BENICAR HCT 40-25 MG TABLET changed over time?

Over the history we have for it, the NADAC for BENICAR HCT 40-25 MG TABLET has risen 31.9%. It has been tracked across 184 weekly CMS publications since Jan 18, 2023.

What are the highest and lowest recorded NADAC prices for BENICAR HCT 40-25 MG TABLET?

Since Jan 18, 2023, the NADAC for BENICAR HCT 40-25 MG TABLET has ranged from a low of $11.8660 (Jan 18, 2023) to a high of $15.7729 (Mar 11, 2026), with a median of $14.1941 per EA.

Are there cheaper alternatives to BENICAR HCT 40-25 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of BENICAR HCT 40-25 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BENICAR HCT 40-25 MG TABLET?

BENICAR HCT 40-25 MG TABLET (NDC 00713086530) is labeled by Cosette Pharmaceuticals, Inc., and CMS classifies it as a brand product.